Previous 10 | Next 10 |
2024-01-26 09:33:10 ET More on Processa Pharmaceuticals Processa stock rallies on NGC-Cap development update Processa Pharmaceuticals to effect 1-for-20 reverse stock split to regain compliance with Nasdaq rule Seeking Alpha’s Quant Rating on Processa Pharmace...
2024-01-26 09:19:36 ET Losers: TC BioPharm ( TCBP ) -21% . Mobilicom Limited ( MOB ) -21% announces $2.95 Million registered direct offering . LAVA Therapeutics ( LVTX ) -14% . Evaxion Biotech ( EVAX ) -13% . Nxu ( NXU ) -13% ...
HANOVER, Md., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety f...
2024-01-26 08:32:05 ET Losers: Aclarion ( ACON ) 119% . Panbela Therapeutics ( PBLA ) 59% . Processa Pharmaceuticals ( PCSA ) 29% . Corbus Pharmaceuticals Holdings ( CRBP ) 23% . as targeting antibody drug conjugate demonstrates encouragin...
2024-01-26 08:21:02 ET Aclarion ( ACON ) +113% . Panbela Therapeutics ( PBLA ) +65% FORM S-1/A | Securities Registration Statement. TC BioPharm (Holdings) ( TCBP ) +17% . Ucommune International ( UK ) +17% . Processa Pharma...
2024-01-25 12:38:47 ET Gainers: Onconetix ( ONCO ) +161% . Processa Pharmaceuticals ( PCSA ) +109% . Rail Vision Ltd RVSN +78% . LAVA Therapeutics LVTX +38% . Vera Therapeutics VERA +38% . Prairie Operating Co PROP +29% . Clearmi...
2024-01-25 10:00:05 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...
2024-01-25 08:59:14 ET DENVER, Colo., Jan. 25, 2023 (www.247marketnews.com)- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) reported, this morning, the... For further details see: Processa Pharmaceuticals (NASDAQ: PCSA) Reports Successful Phase 1b Safety Evaluation Data
Next Generation Capecitabine (NGC-Cap) provides patients with 2-10 times greater exposure to its 5-FU cancer treatment metabolite than capecitabine administration NGC-Cap was better tolerated with positive preliminary efficacy results than FDA-approved capecitabine HANOVER, MD, Jan....
2024-01-23 08:25:53 ET More on Pre-market losers & stocks. Mesoblast Has Major Hurdles Holding The Fort: Mesoblast's Path Towards Overcoming FDA Rejection Mesoblast rises after cell therapy gets FDA rare pediatric disease designation MSP Recovery stock tu...
News, Short Squeeze, Breakout and More Instantly...
Processa Pharmaceuticals Inc. Company Name:
PCSA Stock Symbol:
OTCMKTS Market:
Processa Pharmaceuticals Inc. Website:
Processa Pharmaceuticals (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, has named a new chief financial officer. According to the announcement, Russell L. Skibsted has accepted the new...
HANOVER, Md., July 17, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, announces the appointment of Ru...
Processa (NASDAQ: PCSA) , a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced positive efficacy results from the preliminary evaluation of its recently completed Phase 1b clinical trial. The...